Exametasim (Exametazimum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Radiopaque means

Included in the formulation
  • Teoksim, 99mTc
    lyophilizate in / in 
    DIAMED, LLC     Russia
  • Ceretec®
    lyophilizate in / in 
    JI Halskea Limited     United Kingdom
    • АТХ:

    V.09.A.A.01   99m Tc-Technetium-exametazime

    Pharmacodynamics:

    Diagnostic radiopharmaceutical.

    A radiopharmaceutical prepared from a lyophilisate and a sodium solution [99mTc] pertechnetate. The degree of accumulation in the brain tissues depends on the state of the cerebral blood flow. The application of the device allows one to identify brain diseases associated with the violation of vascularization with the help of a single-photon emission computed tomography. Tropicity of the drug to leukocytes was used in studies of blood cells. Labeling of leukocytes allows visualization of inflammation foci of different localization.

    Pharmacokinetics:

    After intravenous injection quickly leaves the vascular bed, penetrates the blood-brain barrier and accumulates in the brain tissues in proportion to the activity of cerebral blood flow, the brain firmly binds to specific proteins and other biostructures. Absorption of 3.5-4.5%. The equilibrium concentration persists long enough. After 2 hours, the first signs of slow removal of the isotope from the blood appear, the half-life 16 hours (24 hours with renal elimination). Elimination by the kidneys, appearance 99mTc in urine during the second hour after administration is due to the presence of a second complex that does not possess encephalotropic and does not affect the equilibrium concentration in the tissues of the brain.

    Indications:

    For the diagnosis of brain diseases associated with impaired cerebral circulation (including transient cerebral ischemia, stroke, epilepsy, migraine, dementia, tumors); visualization of inflammatory foci of different origin.

    ICD-10

    XX.Y40-Y59.Y57.6   Other diagnostic drugs

    Contraindications:

    General clinical contraindications to the use of radionuclide studies, pregnancy, lactation (within 24 hours after drug administration).

    Carefully:

    Radiation sickness.

    Efficacy and safety of use in children have not been studied.

    Pregnancy and lactation:

    The category of recommendations is not defined. Qualitative and well-controlled studies on humans and animals have not been conducted. Do not apply!

    Discard lactation for 24 hours after drug administration.

    Dosing and Administration:

    Intravenously. Investigation of the blood circulation of the brain. The preparation is prepared immediately before the test by adding 5 ml of sodium [99mTc] pertechnetate to the vial with lyophilizate.A solution of sodium [99mTc] pertechnetate should be obtained no later than 24 hours after the previous elution of the technetium-99m generator and should be used to prepare the preparation within 2 hours. The finished preparation can be stored for no more than 30 minutes.

    The recommended dose is 0.5 mg d, l-HMPAO isomer labeled 185-740 MBq of technetium-99m. One-photon emission computer tomography is used for evaluation, which is carried out according to a known procedure 10-15 min after the drug administration. Plane tomography is performed in four projections.

    Detection of foci of inflammation: intravenously administered activity - 370-450 MBq. The examination is carried out 1 h and 4 h after the administration. The received scintigrams are evaluated visually.

    Radiation loads during the evaluation of the perfusion of the brain (mGr / MBq): tear glands - 0.069, gall bladder - 0.055, kidneys - 0.037, thyroid - 0.03, upper part of the large intestine - 0.027, liver - 0.018, small intestine - 0,016, the lower part of the large intestine - 0,012, the bladder - 0,011, the brain - 0,008, the ovaries - 0,006, the testes - 0,001; after intravenous administration of labeled leukocytes (mGr / MBq): spleen - 0,157, liver - 0,024, red bone marrow - 0,005, bladder - 0,006,ovaries - 0.004; The effective equivalent dose for the assessment of the perfusion state of the brain (mSv / MBK) is 0.0178, after intravenous administration of labeled leukocytes, 0.0165.

    Side effects:

    Hypersensitivity, metallic or bitter taste in the mouth, skin hyperemia, headache.

    Overdose:

    Not described. Treatment is symptomatic.

    Interaction:

    Not described.

    Special instructions:

    Work with the drug should be carried out in accordance with the "Basic Sanitary Rules for Ensuring Radiation Safety" (OSPORB-99).

    Instructions
    Up